4.7 Review

The CD38 glycohydrolase and the NAD sink: implications for pathological conditions

Journal

AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
Volume 322, Issue 3, Pages C521-C545

Publisher

AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajpcell.00451.2021

Keywords

CD38; diseases; NAD metabolism

Funding

  1. Helen Diller Family Foundation
  2. Glenn Foundation for Medical Research via the Paul F. Glenn Laboratories for the Biology of Aging
  3. Calico Life Sciences LLC
  4. National Institute on Aging [AG-26094, AG58812]
  5. National Cancer Institute [CA233790]

Ask authors/readers for more resources

Nicotinamide adenine dinucleotide (NAD) plays a crucial role in cellular processes and its homeostasis is essential for health and disease. CD38 enzyme is a key regulator of NAD homeostasis and dysregulation of CD38 can contribute to various diseases.
Nicotinamide adenine dinucleotide (NAD) acts as a cofactor in several oxidation-reduction (redox) reactions and is a substrate for a number of nonredox enzymes. NAD is fundamental to a variety of cellular processes including energy metabolism, cell signaling, and epigenetics. NAD homeostasis appears to be of paramount importance to health span and longevity, and its dysregulation is associated with multiple diseases. NAD metabolism is dynamic and maintained by synthesis and degradation. The enzyme CD38, one of the main NAD-consuming enzymes, is a key component of NAD homeostasis. The majority of CD38 is localized in the plasma membrane with its catalytic domain facing the extracellular environment, likely for the purpose of controlling systemic levels of NAD. Several cell types express CD38, but its expression predominates on endothelial cells and immune cells capable of infiltrating organs and tissues. Here we review potential roles of CD38 in health and disease and postulate ways in which CD38 dysregulation causes changes in NAD homeostasis and contributes to the pathophysiology of multiple conditions. Indeed, in animal models the development of infectious diseases, autoimmune disorders, fibrosis, metabolic diseases, and age-associated diseases including cancer, heart disease, and neurodegeneration are associated with altered CD38 enzymatic activity. Many of these conditions are modified in CD38-deficient mice or by blocking CD38 NADase activity. In diseases in which CD38 appears to play a role, CD38-dependent NAD decline is often a common denominator of pathophysiology. Thus, understanding dysregulation of NAD homeostasis by CD38 may open new avenues for the treatment of human diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available